Implementation of Disclosure Legislation in Massachusetts National Disclosure Summit March 6, 2009 Allan Coukell, Director of Policy.

Slides:



Advertisements
Similar presentations
Introduction to Existing State Disclosure Laws and Regulations Summit on Disclosure, Transparency and Aggregate Spend For Drug, Device and Biotech Companies.
Advertisements

PwC Medical Device Compliance Survey Discussion of Survey Results.
1 October 16, Secretary of the Department of Administration, Chair Director of the Public Employees Insurance Agency Secretary of the Department.
Pharmaceutical and Medical Device Manufacturer Conduct Melissa J. Lopes, Deputy General Counsel Massachusetts Department of Public Health.
Continuing Professional Development Conflict of Interest This presentation has been developed by the COI Working Group to assist in the implementation.
Pharmaceutical Compliance Current Trends: Hot Button Issues to Look at this Year in Sales, Marketing, Clinical, Medical Affairs and Government Pricing.
Presented by Elena Chan, UCSF Pharm.D. Candidate Tiffany Jew, USC Pharm.D. Candidate March 14, 2007 P HARMACEUTICAL C ONSULTANTS, I NC. P RO P HARMA HIPAA.
HIPAA Privacy Rule Training
Copyright Eastern PA EMS Council February 2003 Health Information Portability and Accountability Act It’s the law.
TM The HIPAA Privacy Rule: Safeguarding Health Information in Research and Public Health Practice Centers for Disease Control and Prevention Beverly A.
COMPLYING WITH HIPAA PRIVACY RULES Presented by: Larry Grudzien, Attorney at Law.
Achieving Better Care by Monitoring All Prescriptions (ABC-MAP) Act 191 of 2014 Board Meeting April 8, 2015.
Ethics 101 Part II for Lobbyists Connecticut Registered Lobbyists
Marketing to Doctors – Payments for Loyalty Julie Brill Assistant Attorney General Vermont Attorney General ’ s Office Montpelier,
Pharmaceutical Compliance Congress: “State of the States” October 27, 2008 Janice G. Cunningham Jeffrey L. Handwerker.
1 Physician-Industry Transparency: The U.S. Physician Payment Sunshine Act.
PA/FOIA INTERFACE OSD/JS Privacy Office (703)
Sarbanes-Oxley Act. 2 What Is It? Act passed by Congress in response to the recent and continuing corporate scandals. Signed into law July 30, Established.
Institutional Memberships November Institutional Memberships New Operational Guideline: Memberships Paid by University Funds can be found at
Fraud, Waste & Abuse DEFICIT REDUCTION ACT OF 2005 Presented by: MARCH Vision Care, 2013.
The Third Annual Medical Device Regulatory, Reimbursement and Compliance Congress Compliance Best Practices in a Post Orthopedic Environment David Matyas.
The Prescription Project: Ending Conflicts of Interest; Promoting Evidence-Based Prescribing Marcia Hams, Director of Prescription Policy Initiatives The.
# Operating Under the New Compliance Environment: Considerations for the Pharmaceutical Industry The Impact of the new Medicare Prescription Drug benefit.
Open Payments Act AKA the ‘Sunshine Act’ Open Payments Act AKA the ‘Sunshine Act’ Public Postings of Physician Ownership, Investments, & Transfers of Value.
VCU School of Medicine Policy on Industry Relations Effective July 1, 2009.
HIPAA PRIVACY AND SECURITY AWARENESS.
Voluntary Codes MassMEDIC Meeting Are You Ready to Comply with Massachusetts’ New Pharmaceutical and Medical Device Code of Conduct Law? Linda D. Bentley,
© 2008 Foley Hoag LLP. All Rights Reserved. 1 The New Massachusetts Pharmaceutical & Medical Device Marketing Regulations How to Address and Overcome Likely.
New Staff Orientation: Industry Relations Emory School of Medicine Zainab R. Wurie, JD July 15, 2014.
State Ethics & Lobbying Laws for Pharmaceutical and Medical Device Companies John T. Bentivoglio (202) Steve Benz
Health Insurance Portability and Accountability Act (HIPAA)
Pitfalls and Lessons Learned: Advanced Implementation Strategies for a Compliant Grant Process National CME Audioconference December 9, 2008.
Coding Compliance Plan July 12, Benefits of a compliance program  To demonstrate our commitment to honest and responsible conduct, decrease the.
CONFLICTS OF INTEREST PRESENTED BY THE UMMC OFFICE OF INTEGRITY AND COMPLIANCE.
1 Strategies for a Compliant Grant Process CIA Monitoring Obligations A. Monica Jonhart Director-U S Pharmaceuticals Compliance Bristol-Myers Squibb.
© 2005 AMERICAN BANKERS ASSOCIATION BANKERS Service Provider Compensation – Are There New Limits? April 9, 2008 Lisa J. Bleier Center.
Managing Your Grant Award August 23, 2012 Janet Stoeckert Director, Research Administration Sr. Administrator, Basic Sciences Keck School of Medicine 1.
1 Pharmaceutical and Medical Device Manufacturer Conduct Melissa J. Lopes, Deputy General Counsel Massachusetts Department of Public Health PHC Meeting.
Key Compliance Risks in Clinical Trials Kathleen Meriwether Principal, ERNST & YOUNG, LLP Fraud Investigation & Dispute Services.
Vendor Relations Policy. Why Is There A Policy? The Patient Protection and Affordable Care Act was signed into law March 23, The new law contains.
+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.
A Focus on CME and Grants Nancy Coddington, PhD Senior Director, Compliance Operations AstraZeneca Pharmaceuticals LP And Terry Hisey Deputy Managing Principal.
Understanding HIPAA (Health Insurandce Portability and Accountability Act)
WHAT STAKEHOLDERS NEED TO KNOW ABOUT THE CME/SUNSHINE ACT PROVISION OF THE ‘21 ST CENTURY CURES ACT’ JULY 14,
Fight On Training on NIH Conflict of Interest Rule and Introduction to diSClose Dan Shapiro Director, Research Compliance Ben Bell Manager, Research Compliance.
Partners Conflict of Interest Policy and Reporting October 11, 2012.
1 Continuing Medical Education and Industry Sponsorship The Pharma, Biotech and Device Colloquium Princeton, NJ June 7, 2005 Julie K. Taitsman, M.D., J.D.
1 Harvard University Cambridge, MA March 29, 2007 Medical Device Congress AdvaMed’s Efforts to Promote Compliance Christopher L. White, Esq. Executive.
Welcome….!!! CORPORATE COMPLIANCE PROGRAM Presented by The Office of Corporate Integrity 1.
ROPES & GRAY LLP The Compliance Environment and Grant Process: Oversight and Response in the Pharmaceutical Industry Howard L. Dorfman December 9, 2008.
The Physician Payments Sunshine Act Legislation Ann Leopold Kaplan October 27, 2008.
California’s New Compliance Law Kelly N. Reeves
Japan Fair Competition Code for Medical Devices Industry (JFCC-MDI)
Second Annual Medical Research Summit March 25, 2002 Washington, D.C.
Compliance Issues in Dealing With Drug and Device Manufacturers Presentation to The Sixth Annual National Congress On Health Care Compliance Paul E. Kalb,
FDA Regulatory and Compliance Symposium Industry Collaboration & Interactions with Health Professionals: Can Conflicts of Interest be Properly Managed?
FERPA for the Financial Aid Office NCASFAA Fall Conference November 2012.
The Georgia Open Records Act and ferpa
Disclosure of Financial Interest Policy. Medical Staff Policy Approved by the MEC’s Aimed at protecting the integrity of the LMHS Medical Staffs Requires.
What is HIPAA? HIPAA stands for “Health Insurance Portability & Accountability Act” It was an Act of Congress passed into law in HEALTH INSURANCE.
HIPAA CONFIDENTIALITY
National Pharma Audioconference Revised PhRMA Code: Key Provisions
Analysis of the Proposed Sunshine Rule: Legal Considerations
The Physician Payments Sunshine Act
Lilly Grant Funding Disclosure May 27, 2008
An Introduction to the Sunshine Act
California’s “Comprehensive Compliance Program” Law
Analysis of Final HIPAA Privacy Modification Rule
Updates to the PhRMA Code on Interactions with Healthcare Professionals National Pharma Audioconference August 5, 2008.
Implementing Controls Around Grants, Consulting Agreements, CME, Preceptorships, and Other Promotional Practices Paul E. Kalb Heidi C. Chen Fourth Annual.
Presentation transcript:

Implementation of Disclosure Legislation in Massachusetts National Disclosure Summit March 6, 2009 Allan Coukell, Director of Policy

Sources of funding: The Pew Charitable Trusts Conflicts of interest: none

Recent State Activity on Disclosure

Current State Laws on Disclosure Minnesota (1993): Public disclosure of all payments over $100. Ban on gifts over $50; education and other exemptions. Vermont (2002): Disclosure of individual MD payments to Attorney General; aggregated for public. Maine (2003): Not yet implemented. Non-public disclosure of individual payments >$25. West Virginia (2004): Broad disclosure but no individual MD names. Washington DC (2005): Non-public disclosure. Annual reports to DPH. Massachusetts (2008, rules pending): Public disclosure of all payments except research. Ban on gifts, meals, entertainment, travel & expenses.

Physician Payments Sunshine Act

Past Action in MA Past Action in MA Fair Pricing Act –Sponsored by Sen. Montigny –Discount program for seniors –Statewide uniform PDL, PA protections, bulk purchasing –Gifts ban and disclosure –Did not pass

Massachusetts Cost & Quality Law

Requires DPH to write a marketing code of conduct that is "no less restrictive" than PhRMA and AdvaMed codes Requires public disclosure of all payments over $50 made to doctors (with certain exclusions) Funds an evidence-based prescriber education program

Cost & Quality Timeline Jan 07: MA Cost and Quality bill initially introduced Feb 08: Reintroduction. MA Senate President files 17-point cost and quality bill including disclosure and gifts ban and academic detailing program Apr 08: C&Q bill passed Senate with gifts ban and prescriber education Prescriber education in final budget Jul 08: C&Q bill passed House with prescriber education; no gifts ban or disclosure; industry codes to be submitted; ban on data mining In Conference, gifts ban, disclosure, and prescriber education are preserved, data mining ban is dropped. Aug 08: Bill passes legislature and is signed into law Dec 08: DPH releases set of draft regulations.

C&Q Law: Gifts & Meals Sponsored meals must accompany an informational presentation and must be conducted in the doctors office or hospital setting. Industry may not pay for meals that are part of a recreational event. Industry may not provide any recreational items.

C&Q Law : CME & Events Industry may not sponsor CME that does not meet ACCME standards. Industry may not provide payment for attendance or travel support to attendees of off-site CME or other events. Industry may not provide direct payment for meals during CME, professional meetings, and events.

C&Q Law: Allowed Distribution of peer-reviewed information Samples for patient use Compensation for substantial professional or consulting services in conjunction with research or a clinical trial Training on devices

C&Q Law: Disclosure Annual disclosure of payments to prescribers/ purchasers. Made public on a searchable website. What: fee, payment, subsidy, other economic benefit Greater than $50, provided directly or through a company’s agents To: Physician, hospital, nursing home, pharmacist, health benefit plan administrator, heath care practitioner, any other authorized to prescribe, dispense or purchase prescription drugs or devices. Including: value, nature, purpose, particular recipient Funding: user-fee based (to be established by DPH) Enforcement: DPH will report any payment in violation of the code of conduct to the AG. Penalties of not more than $5000 per violating transaction

C&Q Law: Industry must… Institute mechanisms for complying with the code of conduct by July 1, 2009 Provide a regular training program for employees on code of conduct compliance Conduct annual audits to monitor compliance among employees Adopt policies and procedures for investigating noncompliance and take corrective action Identify a compliance officer for operating and monitoring code of conduct Submit an annual report to DPH including: a description of its training program; name and contact for its compliance officer; and certification it has completed its annual audit.

DPH Draft Regulations Released December 12, 2008 for comment Further specify Code of Conduct and disclosure requirements. Largely conform to the PhRMA guidelines DPH is waiting to see if further budget cuts are made before proceeding with the prescriber education program.

Expanded in DPH Draft Regulations: Gifts & Meals –All meals provided must be modest and occasional –Industry may not provide payments or “complimentary” items either directly or indirectly except as compensation for bona fide services CME –Companies must separate its CME grant-making functions from its sales/ marketing dept. –Companies must not have any input on the content or faculty for funded programs –make payments for events directly to the conference or meeting organizers

Payments for Services (may be provided if:) –the compensation is subject to a written contract –the compensation is fair market value –There is a legitimate need for the service –There is a connection between the competence/expertise of the consultant and the purpose of the arrangement –Only the number of consultants needed are retained –The company retains records about the arrangement and makes appropriate use of the services provided –The venue and circumstances of any meeting are appropriate Expanded in DPH Draft Regulations:

Disclosure –Payments in connection with the company’s sales and marketing activities will be disclosed. This excludes compensation related to research or clinical trials, and gifts given for educational and practice-related purposes, such as textbooks and computers. –The disclosure must be accompanied by a fee of $2000 –Reports must be made on a standardized reporting form –The first report will cover July 1, 2009 through Dec 31, 2009 –Companies shall not knowingly structure payments to circumvent the disclosure requirement Expanded in DPH Draft Regulations:

Other Disclosures –Industry must require speakers and commercial consultants to disclose their roles as such if they are also members of formulary/clinical guideline committees. Use of Prescribing Information –All companies that use prescriber-identifiable prescribing information for marketing must: Maintain the confidentiality of the data Develop policies re: the use of the data, educate employees agents about the policies and identify disciplinary actions for violations Comply with requests of providers to not provide his/her data to sales reps Expanded in DPH Draft Regulations:

Issues being discussed General business environment Payments related to research Small gifts Gifts with educational value Industry support of CME, professional meetings, and events

General Business Environment Concern: The C&Q measures will drive business from the state Response: Since Minnesota’s gift ban and disclosure legislation passed in the early 1990s, pharmaceutical industry jobs there grew by over 36%, compared with 19.7% nationwide. Disclosure of all relationships will allow the state and the public to understand the financial relationships between physicians and companies.

Payments Related to Research Concern: disclosing payments made to researchers will harm a company’s competitive edge. Response: The information being disclosed is not private. Pharmaceutical companies and providers already disclose information about clinical trials to the FDA and NIH. The FDA publishes this information on a public database.

Small Gifts and Educational Gifts Concern: Banning small gifts will harm the relationship between industry and doctors, and will harm businesses that manufacture these gift-products. Response: The power of small, repeated gifts to influence decision-making has been extensively documented. Concern: Banning educational gifts does a disservice to patients and prevents industry from sharing information. Response: Educational gifts are still part of marketing. The law does not impede information sharing. Sales representatives can continue to visit doctor’s offices and provide information about their products.

One appeal to the MA House

Industry Support of CME & events Concern: Prohibiting industry from providing direct sponsorship to CME or from directly providing meals at professional meetings and events will drive symposia from the state. Caterers claim they will lose $40 million. Response: ACCME regulations and PhRMA guidelines already largely conform with the C&Q law. The Minnesota Convention Center Bureau say they have not seen any dip in convention attendance since enactment of MN’s gift ban and disclosure legislation in 1993.

Thank you Questions, discussion? Allan Coukell, Director of Policy Tel: